ARCT

SEC source: 0001193805-22-001746 · e618136_4-kummerfeld.xml · derivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-12-09

F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001718 · e618117_4-markels.xml · derivative · entry 2

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,986

Underlying: Common Stock · 6,986 shares

Expires 2032-12-08

F2 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board, representing an estimated six months of service.

SEC source: 0001193805-22-001718 · e618117_4-markels.xml · derivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-12-08

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors (the "Board").

SEC source: 0001193805-22-001614 · e618061_4-payne.xml · nonDerivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,480,097

F1 · price: Represents the purchase price paid by the Reporting Person for the shares of common stock, $0.001 par value per share, of the Registrant, in an open market transaction.

SEC source: 0001193805-22-001207 · e621887_4-sassine.xml · nonDerivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,303

F1 · shares: Represents shares of common stock purchased by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2022.

SEC source: 0001193805-22-001024 · e621785_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-22-001021 · e621782_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-22-001020 · e621781_4-holmes.xml · derivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-22-001023 · e621784_4-marquet.xml · derivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-22-001022 · e621783_4-jing.xml · derivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-22-001003 · e621776_4-kummerfeld.xml · derivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2031-12-10

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001000 · e621771_4-sassine.xml · derivative · entry 1

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2031-12-10

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001001 · e621772_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-12-10

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-001002 · e621773_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2031-12-10

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-000999 · e621770_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-12-10

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-22-000015 · e621194_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 594,448

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001193805-21-001784 · e621144_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 602,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001193805-21-001726 · e621144_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 606,181

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001193805-21-001718 · e621146_4-jing.xml · derivative · entry 2

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,699

Underlying: Common Stock · 6,699 shares

Expires 2031-12-06

F2 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the annual grant to the Reporting Person as a member of the Board, prorated based on the date the Reporting Person was appointed to the Board, representing an estimated six months of service.

SEC source: 0001193805-21-001718 · e621146_4-jing.xml · derivative · entry 1

Marantz Jing L. · CIK 0001834528 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-12-06

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a two year period from the date of grant. This represents the initial grant to the Reporting Person as a member of the Board of Directors (the "Board").

SEC source: 0001193805-21-001522 · e621049_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 612,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 1, 2021 with sale prices ranging from $43.17 to $45.42 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-001408 · e620990_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 622,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 1, 2021 with sale prices ranging from $43.04 to $47.91 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-001272 · e620921_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 632,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 1, 2021 with sale prices ranging from $53.91 to $57.26 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-051182 · doc4.xml · nonDerivative · entry 2

Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400,000

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-21-051182 · doc4.xml · nonDerivative · entry 1

Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,475,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193805-21-001112 · e620845_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 642,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on August 3, 2021 with sale prices ranging from $40.00 to $40.57 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-000925 · e620745_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-18

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-21-000926 · e620746_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-18

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-21-000927 · e620747_4-holmes.xml · derivative · entry 1

HOLMES EDWARD W · CIK 0001197099 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-18

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-21-000928 · e620748_4-marquet.xml · derivative · entry 1

Marquet Magda · CIK 0001631486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-18

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-21-000929 · e620749_4-parschauer.xml · derivative · entry 1

Parschauer Karah Herdman · CIK 0001677455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-18

F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.

SEC source: 0001193805-21-000455 · e620448_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 652,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on April 1, 2021 with sale prices ranging from $41.55 to $44.26 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-000323 · e620351_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 662,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 1, 2021 with sale prices ranging from $53.34 to $55.36 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-000124 · e620251_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 672,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on February 1, 2021 with sale prices ranging from $73.19 to $76.60 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-21-000014 · e620192_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 682,548

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on January 4, 2021 with sale prices ranging from $43.74 to $50.36 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001193805-20-001611 · e620165_4-kummerfeld.xml · derivative · entry 1

Kummerfeld Keith C · CIK 0001762749 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2030-12-18

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-001608 · e620162_4-sassine.xml · derivative · entry 2

SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-18

F2 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-001609 · e620163_4-payne.xml · derivative · entry 1

Payne Joseph E · CIK 0001727315 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2030-12-18

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-001610 · e620164_4-chivukula.xml · derivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-18

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-001607 · e620161_4-hughes.xml · derivative · entry 1

Hughes Steven George · CIK 0001747528 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-18

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-001606 · e620160_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-12-18

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001209191-20-062733 · doc4.xml · nonDerivative · entry 2

Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200,000

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $106.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001209191-20-062733 · doc4.xml · nonDerivative · entry 1

Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,557,745

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $116.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193805-20-001491 · e620114_4-chivukula.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 692,548

F1 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on December 1, 2020 with sale prices ranging from $87.29 to $100.43 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-20-030320 · doc4.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 702,548

F1 · price: The reported price is the weighted average price per share sold by the reporting person. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 2, 2020 with sale prices ranging from $53.04 to $56.80 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-20-026884 · doc4.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 712,548

F1 · price: The reported price is the weighted average price per share sold by the reporting person. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 1, 2020 with sale prices ranging from $41.57 to $44.04 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-20-024363 · doc4.xml · nonDerivative · entry 1

Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 722,548

F1 · price: The reported price is the weighted average price per share sold by the reporting person after adjustment for a broker's error. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 3, 2020 with sale prices ranging from $42.60 to $47.93 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001193805-20-001022 · e619870_4-kurata.xml · derivative · entry 1

Kurata Lance · CIK 0001820961 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-08-09

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 10, 2021, with the remainder vesting in 36 successive equal monthly increments thereafter.

SEC source: 0001193805-20-000742 · e619721_4-farrell.xml · derivative · entry 1

FARRELL PETER C · CIK 0001186102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-21

F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant.

SEC source: 0001193805-20-000743 · e619722_4-barlow.xml · derivative · entry 1

BARLOW JAMES F · CIK 0001190637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-21

F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant.